Eosinophilic Esophagitis (EoE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Eosinophilic Esophagitis (EoE), also known as the "asthma of the esophagus," is a chronic condition rooted in allergies and immune responses. It shares numerous clinical and pathophysiological features with asthma. This ailment is characterized by inflammation in the esophagus, making it an atopic inflammatory disorder of this organ. Age-related variations in how it manifests have been observed in children and adults. The most frequent initial symptoms in adults include dysphagia, food blockages, heartburn, and chest pain. Strikingly, about 50% of adult patients who initially report food blockages are eventually diagnosed with EoE. In contrast, children tend to exhibit vomiting, heartburn, regurgitation, emesis, and abdominal pain more frequently. Dysphagia and food blockages, typical adult complaints, are rarely seen in younger children but become more common in individuals over 12. The gold standard for diagnosing EoE relies on biopsy results showing increased eosinophils within the esophageal epithelium without concurrent eosinophilic infiltration in the stomach or duodenum. Most EoE patients do not respond well to acid-suppression therapy, and up to 75% of them have a personal or family history of atopic conditions such as asthma, eczema, and rhinitis, as well as allergies to environmental factors or foods.
·
In pediatric cases, the most common
comorbidities include asthma (13.4%), gastrointestinal disorders of the
stomach, duodenum, and intestine (7.26%), allergies (7.01%), and
gastroesophageal reflux disease (GERD) (3.69%).
Thelansis’s
“Eosinophilic Esophagitis (EoE) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Eosinophilic
Esophagitis (EoE) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Eosinophilic
Esophagitis (EoE) across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Eosinophilic
Esophagitis (EoE) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment